A compounding pharmacy may prepare an ivermectin product only when a prescriber writes a valid prescription for a named individual patient, and what comes out of that pharmacy is not an FDA-approved drug. Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a(a)) exempts a compounded product from the approval requirement in section 505 precisely because it is not approved — that exemption is conditioned on the product being "compounded for an identified individual patient based on the receipt of a valid prescription order." That is a narrower lane than most websites suggest, and it sits alongside the approved products that already exist.

This page explains what an ivermectin compounding pharmacy may lawfully make, what the "essentially a copy" restriction does to a request for a plain ivermectin tablet or cream, why a 503B outsourcing facility is a different legal animal from a corner compounder, and how to check a compounder's credentials yourself. All federal facts here were checked against primary sources as of 28 September 2026.

Key takeaways

  • A compounded ivermectin preparation is never FDA-approved. Under 21 U.S.C. 353a(a), the compounding exemption applies only because section 505 approval does not.
  • Compounding is not an over-the-counter route. Federal law ties the 503A exemption to a valid prescription for an identified individual patient.
  • FDA guidance restricts compounding drugs that are "essentially a copy" of a commercially available product (503A) or of an approved drug (503B) — and approved ivermectin tablets, 1% cream and 0.5% lotion already exist in the US.
  • Beyond-use dates on compounded preparations are assigned under USP standards and are typically far shorter than a manufactured product's expiration date.
  • Animal ivermectin products — pastes, drenches, injectables — are labeled for animal use only and are not approved for people; FDA's 2020 stakeholder letter states that people should never take animal drugs.

What compounding is, and what it is not

Technician in gown and hairnet at the anteroom door of an outsourcing facility cleanroom.

Compounding is the preparation of a medicine by a licensed pharmacist or physician for a particular patient: changing a dosage form, removing an excipient, adjusting a strength that is not manufactured. Under 21 U.S.C. 353a(a), a qualifying compounded product is exempt from three requirements that apply to manufactured drugs — current good manufacturing practice under section 501(a)(2)(B), adequate directions for use under section 502(f)(1), and premarket approval under section 505.

What compounding is not: a manufacturing workaround, a research pathway, or a way to obtain a prescription medicine without a prescription. It also is not a claim of equivalence. Because a compounded preparation is exempt from approval rather than approved, no FDA review of its safety, effectiveness, strength or stability has taken place. A new drug that is not covered by an effective approval and is shipped in interstate commerce runs into 21 U.S.C. 355(a) and the prohibited-acts provisions at 21 U.S.C. 331.

503A pharmacies and 503B outsourcing facilities: two different legal categories

Pharmacy shelf of plain manufactured cartons beside a hand-filled compounded ointment jar on a wooden counter.

People searching for 503b ivermectin often assume "503B" means a higher grade of the same thing. The two categories differ in who licenses them, whether patient-specific prescriptions are needed, and which copy restriction applies.

503A pharmacy 503B outsourcing facility
Primary oversight State board of pharmacy; FDA may inspect Registers with FDA; inspected on a risk-based schedule
Prescription Valid prescription for an identified individual patient (21 U.S.C. 353a(a)) May supply office stock without patient-specific prescriptions
CGMP Exempt under 353a(a) Must comply with CGMP
Copy restriction May not compound "regularly or in inordinate amounts" drugs that are essentially copies of a commercially available drug product May not compound a drug that is "essentially a copy of one or more approved drugs"
FDA approval status of output Not approved Not approved

FDA sets out both copy standards in separate guidance documents for industry, one addressing section 503A and one addressing section 503B.

The essentially-a-copy rule, and what it means when an approved product already exists

Pharmacy technician writing on a blank label for a freshly compounded jar under a desk lamp.

This is the rule that most often blocks a routine request for compounded ivermectin, because approved ivermectin products exist in three dosage forms. FDA's Orange Book, in the edition current through September 2026, lists 15 distinct human ivermectin applications across 17 product rows, and the only approved human dosage forms are the oral tablet, the 1% topical cream and the 0.5% topical lotion. Oral tablets are listed at 3 mg and 6 mg only.

So a request for "ivermectin 3 mg tablets, compounded" is a request for something that is commercially available. A request for a 1% ivermectin cream is a request for something Galderma markets as SOOLANTRA under NDA 206255, approved 19 December 2014 for inflammatory lesions of rosacea, with three approved generics (Teva ANDA 210019, 13 September 2019; Padagis Israel ANDA 210225, 13 April 2020; Zydus ANDA 215210, 2 August 2022). Compounded strengths or vehicles that differ from the approved cream are a different question from copying it — see our explainer on compounded rosacea creams for how prescribers frame that difference. Under both FDA copy guidances, a prescriber's documented determination that a change makes a clinical difference for that patient is central; a preference or a price argument is not the same thing.

Why a compounded preparation is never FDA-approved, whatever the website says

Woman at a kitchen table checking a pharmacy licence lookup on a laptop turned away from the camera.

If a seller advertises "FDA-approved compounded ivermectin," the phrase is self-contradictory. The 503A exemption exists because section 505 approval does not apply. There is no NDA or ANDA number for a compounded preparation, no Orange Book listing and no therapeutic-equivalence rating. Sites that blur this line often go further and offer products with no lawful basis at all; we cover those separately under products with no approval at all. FDA's consumer update on ivermectin, current as of 5 April 2024, also states plainly that it has not authorized or approved ivermectin for preventing or treating COVID-19 in humans or animals.

Bulk drug substances: the list a compounder may work from

A 503A pharmacy cannot start from any powder it can buy. The active substance must be the subject of an applicable USP or NF monograph, be a component of an FDA-approved drug product, or appear on the 503A bulks list codified at 21 CFR 216.23(a). Section 503A additionally requires bulk substances to be made by an FDA-registered establishment and to arrive with a valid certificate of analysis.

FDA also runs an interim policy for substances nominated for that list. According to the Federal Register notice of 7 January 2025 announcing the final 2024 interim policy guidance, FDA does not intend to categorize bulk drug substances nominated on or after that publication date; substances previously placed in Category 1 remain usable under the described conditions. We could not confirm from FDA's published bulks-list pages, as of 28 September 2026, that ivermectin API appears on the 503A bulks list itself — a compounder relying on a different statutory basis should be able to say which one.

Veterinary compounding is stricter in one respect worth knowing: 21 CFR 530.13(a) states that "Nothing in this part shall be construed as permitting compounding from bulk drugs." Separately, approved animal ivermectin products such as the 1.87% equine paste (ANADA 200-390) and IVOMEC injection (NADA 128-409) are labeled for animal use only and are not approved for people.

Beyond-use dates and why they are much shorter than an expiry date

A manufactured product carries an expiration date supported by stability data filed with FDA. A compounded preparation carries a beyond-use date (BUD), assigned under USP standards — USP <795> for nonsterile preparations, which uses water activity to judge susceptibility to microbial growth and hydrolysis, and USP <797> for sterile preparations, which sorts them into categories by the conditions under which they were made. A BUD is generally much shorter, sometimes dramatically so, and it assumes the storage conditions the pharmacy specified.

A BUD is a property of the preparation, not of the molecule. It should not be confused with pharmacokinetics: the STROMECTOL label (revision 09/2024) gives a plasma half-life in humans of approximately 18 hours after oral administration, which is a separate measurement entirely — see what the approved labels record about ivermectin's effects.

What the FDA's warning letters in this area have actually alleged

FDA warning letters touching ivermectin have mostly targeted sellers and marketing rather than compounding technique. In the letter to www.ivermectin4covid.com (MARCS-CMS 650184, dated 16 March 2023), FDA stated that the website introduced into interstate commerce misbranded and unapproved new drugs. In the compounding space more broadly, FDA's warning letter to Boothwyn Pharmacy LLC, dated 9 June 2025, addressed animal drugs compounded from bulk drug substances and characterized them as unapproved new animal drugs. FDA also maintains a running public page of compounding inspections, recalls and other actions.

An honest limit: as of 28 September 2026, we did not locate an FDA warning letter whose core allegation was unlawful compounding of ivermectin by a named state-licensed pharmacy. The absence of a letter is not a clearance, and it is not evidence that any particular compounder is compliant.

How to verify a compounder's state licence and 503B registration

  • Check the pharmacy's licence on your state board of pharmacy's online licence lookup, and check the licence in the state where the pharmacy is physically located as well as your own.
  • If the seller claims outsourcing-facility status, confirm it against FDA's registered outsourcing facility information published on FDA's human drug compounding pages. Registration is a fact FDA publishes; a logo on a website is not.
  • Read FDA's compounding inspections, recalls and other actions page for the firm's name.
  • Be wary of any site that ships a prescription medicine without a prescription. FDA's consumer update, current as of 5 April 2024, advises that if a health care provider writes an ivermectin prescription, it should be filled "through a legitimate source such as a pharmacy." Our guide to buying online lawfully covers what a legitimate pharmacy looks like.

Legitimate reasons a prescriber does order a compounded preparation

There are real clinical situations in which a prescriber asks for a compound pharmacy ivermectin preparation rather than a stock product:

  • No approved dosage form fits. The US has no approved oral liquid ivermectin — only tablet, cream and lotion. A patient who cannot swallow tablets or who is fed by tube is the classic example.
  • Weight or age falls outside the labeled range. The STROMECTOL label states that safety and effectiveness in pediatric patients weighing less than 15 kg have not been established, and both of its dosing tables begin at 15 kg.
  • Excipient intolerance. STROMECTOL 3 mg tablets list five inactive ingredients — microcrystalline cellulose, pregelatinized starch, magnesium stearate, butylated hydroxyanisole and anhydrous citric acid powder — and a documented reaction to one of them is a recognized reason to remove it.
  • Veterinary orders. A pharmacist may compound on a veterinarian's order within the limits of 21 CFR part 530; that framework governs veterinarians and confers nothing on human use.

None of these reasons converts the result into an approved product, and none of them supports using a compounded ivermectin preparation for a condition no approved ivermectin label covers.

Frequently asked questions

Is compounded ivermectin FDA approved?

No. The question "is compounded ivermectin fda approved" has a single answer under 21 U.S.C. 353a(a): the compounding exemption operates by setting aside the section 505 approval requirement, so an approved compounded product does not exist as a category.

Can a compounding pharmacy supply ivermectin without a prescription?

Not under the federal 503A conditions, which require a valid prescription order for an identified individual patient. Seven states — Arkansas, Idaho, Iowa, Louisiana, Missouri, Tennessee and Texas — have enacted access laws that let a pharmacy supply human ivermectin without a patient-specific prescription, such as Idaho Code § 37-135 (in force 14 April 2025) and Texas HB 25 (in force 4 December 2025). North Dakota is often counted alongside them, but N.D.C.C. § 43-15-42.4 (in force 15 November 2021) is a shield law rather than an access law: it protects the prescriber or pharmacist from discipline or liability and creates no new route for a patient, who still needs a prescription. All of these laws address prescribing, pharmacist protocols and liability for approved products; none of them makes a compounded preparation FDA-approved.

Is a compounded ivermectin cream the same as the approved 1% cream?

No. The approved cream is a 1% formulation containing 10 mg of ivermectin per gram, applied once daily as a pea-size amount per affected facial area, and its label says it is not for oral, ophthalmic or intravaginal use. A compounded cream has no approved label, no therapeutic-equivalence rating and a pharmacy-assigned beyond-use date.

Can a 503B outsourcing facility make ivermectin for a clinic's shelf?

A 503B facility may supply without patient-specific prescriptions, but it is separately barred from compounding a drug that is essentially a copy of an approved drug — and approved ivermectin tablets, 1% cream and 0.5% lotion are on the market, the lotion having switched from prescription to over-the-counter status on 27 October 2020 under NDA 202736/S-006.

Is compounding cheaper than the approved product?

We cannot verify retail prices from a primary source, and this site does not quote them. For context only, CMS's National Average Drug Acquisition Cost file, effective 23 September 2026, reported $1.99423 per 3 mg ivermectin tablet, $9.80491 per 6 mg tablet, $2.74609 per gram for generic 1% cream and $1.23937 per gram for 0.5% lotion. NADAC is a pharmacy acquisition benchmark, not a consumer price.

Can a compounder use animal-grade ivermectin as a starting material?

No. Animal ivermectin products are labeled for animal use only and are not approved for people, and FDA's stakeholder letter of 10 April 2020 states that people should never take animal drugs. Bulk substances used in human compounding must meet the section 503A sourcing conditions described above.

Sources